Martina Flammer

“Yeah, maybe, Ritu, this is speaking also about the importance of both of those physician and expert communities now to work together and look at their patient population, what might be driving the disease, and if patients continue to exacerbate, is it the underlying COPD, or is it truly bronchiectasis?”

“Yeah, I think one thing I would add here is that you've seen that the agency, the FDA here, has also recognized the potential and plausible hypotheses that TPIP is clinically superior.”

“So we're looking at a phenotype of patients who continue to exacerbate, even though they're optimally treated for CUPD or for asthma already.”